Clinical Trial Update: Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC [Phase 3]

View source ↗

Summary

A Phase 3 trial is investigating whether adding glutamine and the probiotic Lactobacillus reuteri can prevent diarrhea associated with EGFR-targeted TKI therapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutated Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Glutamine (glutamine)
• Lactobacillus reuteri (Lactobacillus reuteri)

Snippet

Sponsor: Instituto Nacional de Cancerologia de Mexico | Conditions: Non-Small Cell Lung Cancer With EGFR Mutation | Phase 3 | Status: RECRUITING